Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 10;14:6332. doi: 10.1038/s41467-023-41828-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Effect of Trametinib (Tram) and Lestaurtinib (Lest) combination on cell viability of wild type (wt) KRAS (H1437, H2126, HCC78, H1993 and H1650) and mutant (mut) KRAS (H1792, H2009, A549, HCC44, H23 and H358) cells treated for 72 h treatment. Tram: 0.5 μM; Lest: 0.625 μM (data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment). B Effect of Tram and Lest combination on cell viability of mut KRAS LUAD cells (H1792, H2009 and A549) grown in 3D culture conditions (72 h drug treatment; n: 3 cell lines). Tram: 0.01–0.05 μM; Lest: 0.05–0.1 μM (data: mean +/− SD; test: one-way ANOVA, Tukey’s adjustment). C Representative images of mut KRAS LUAD cell lines in (B) exposed to the different treatments. Scale bar: 200 μm. D Percent fold change growth of H1792-derived tumors of mice (n: 8 tumors per group) treated with indicated drugs (data: mean +/− SEM; test: Kruskal–Wallis, Dunn’s adjustment). E Waterfall plot of tumors in (C) at the last day of experiment. Ctrl: untreated control; Tram: 1 mg/kg; Lest: 30 mg/kg; Combo: drug combination. F, G Western blot of cleaved PARP expression of mut KRAS (H1792, H2009 and A549; E) and wt KRAS (H1568, H1993 and H1437; F) cell lines 24 h after drug treatment (loading control: GAPDH).